Psychiatric aspects in Parkinsonism treated with L-dopa.
about
Visual hallucinations in the elderly associated with the use of levodopaSelegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease.The pattern of depressive symptoms varies with progression of Parkinson's disease.Does levodopa alter depression and psychopathology in Parkinsonism patients?Management of parkinson's disease--combined therapy with levodopa and thalamotomy.A mouse model of non-motor symptoms in Parkinson's disease: focus on pharmacological interventions targeting affective dysfunctions.Does anxiety cause freezing of gait in Parkinson's disease?Chronic L-dopa decreases serotonin neurons in a subregion of the dorsal raphe nucleusMaladaptive reward-learning and impulse control disorders in patients with Parkinson's disease: a clinical overview and pathophysiology updatePrevalence of psychotic symptoms in a community-based Parkinson disease sampleDepression of Serotonin Synaptic Transmission by the Dopamine Precursor L-DOPANew approaches to understanding hallucinations in Parkinson's disease: phenomenology and possible origins.Potential mechanisms underlying anxiety and depression in Parkinson's disease: consequences of l-DOPA treatment.Mirthful laughter induced by subthalamic nucleus stimulation.Locus coeruleus-pineal melatonin interactions and the pathogenesis of the "on-off" phenomenon associated with mood changes and sensory symptoms in Parkinson's disease.Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease.Psychosis and concurrent impulse control disorder in Parkinson's disease: A review based on a case report.The effects of anxiety and external attentional focus on postural control in patients with Parkinson's disease.Further observations on the unique efficacy of picoTesla range magnetic fields in Parkinson's disease.Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease.Dexamphetamine-induced reduction of P3a and P3b in healthy participants.Neurobiology of Impulse Control Disorders in Parkinson's Disease
P2860
Q28355598-1C3D871A-1500-45DD-88FF-F047E5B677BFQ29994860-9B4B0783-E445-4F12-8C47-86BC05552C53Q33588801-5CF5568B-5179-44EF-AB9A-C0AA6FE92C8FQ33756784-F143C6EA-35B6-46EE-9791-1B2453A05BB7Q33824385-C6FA29E7-4AA3-4F85-B882-C68B52EFCD33Q34094065-54BA5041-693F-40C3-ACE1-D6F23864529AQ34243678-94A0DE11-C7E9-4794-AF0B-E25B93379159Q34360660-FB33EE48-3CA6-4831-AA90-7D4EF3498B0AQ34423280-AF8CD9D2-89CC-4A66-B17A-AA4DB6112F7CQ35201060-9A31B144-5517-4396-97F2-0328D239A86AQ35952108-B8C10334-CE2D-4300-8BCB-7AE450B76E4EQ37021326-64FB2EB8-53FE-43D5-9E1E-BA17A237FF4BQ37771075-3254021B-338C-4768-A764-369C3E6FD6B0Q38553939-D79ADB2C-0300-471F-87AD-A7E58975DE05Q38749646-1142076B-FD27-411F-BC9D-75753A5AE3CEQ45189216-8FCDC7B5-F5E4-4DF3-B820-59610B960F16Q47106246-5026F886-186F-474A-B037-167253A5CE16Q48042463-2F88519D-EB3E-433E-84AF-2739174A0CF8Q48328735-17E82F7B-16D5-4858-8B71-B2EB976209A4Q48401334-4DAB8989-5FC7-46BC-92BC-76B2C232DBF0Q51041372-FB4399F9-4211-47D3-A3BF-7E1B9E6B929DQ57083746-F1255B2D-B510-44F9-8DF6-1E3457538DBE
P2860
Psychiatric aspects in Parkinsonism treated with L-dopa.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 1971
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Psychiatric aspects in Parkinsonism treated with L-dopa.
@en
Psychiatric aspects in Parkinsonism treated with L-dopa.
@nl
type
label
Psychiatric aspects in Parkinsonism treated with L-dopa.
@en
Psychiatric aspects in Parkinsonism treated with L-dopa.
@nl
prefLabel
Psychiatric aspects in Parkinsonism treated with L-dopa.
@en
Psychiatric aspects in Parkinsonism treated with L-dopa.
@nl
P2093
P2860
P356
P1476
Psychiatric aspects in Parkinsonism treated with L-dopa.
@en
P2093
Damãsio AR
Lobo-Antunes J
P2860
P304
P356
10.1136/JNNP.34.5.502
P407
P577
1971-10-01T00:00:00Z